Tirzepatide Guide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist that activates two incretin hormone pathways simultaneously. It is FDA-approved for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound, and has demonstrated superior weight loss outcomes compared to semaglutide in head-to-head trials.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
How Tirzepatide Works
Tirzepatide is a "twincretin" that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying, while GIP activation enhances insulin secretion, reduces glucagon, and may also act directly on fat tissue to improve metabolism. This dual mechanism produces greater weight loss than GLP-1-only agents like semaglutide.[3][5]
Dosing Schedule
Tirzepatide uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
Side Effects
Common: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite, injection site reactions, fatigue. Serious (rare): pancreatitis, gallbladder problems, hypoglycemia (especially with insulin), kidney problems, increased heart rate. Same thyroid tumor precautions as semaglutide apply.[1][3]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
In the SURMOUNT-1 trial (N=2,539), tirzepatide at the 15mg dose achieved an average weight loss of 22.5% over 72 weeks — nearly double the results seen with semaglutide. Participants on 10mg lost an average of 21.4%, and those on 5mg lost 15.0%, all versus 2.5% placebo.[3][4]
Where to Get Tirzepatide
Sellers in our register that will dispense tirzepatide, or a compounded version of it, after an online consultation — shipped to your door.
Trimi Health
Best for: knowing which pharmacy fills the vial — it names VialsRx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Cost Comparison
What each seller in the register charges to start on a compounded GLP-1, cheapest at the top. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[6], and the rules have historically loosened further for any molecule sitting on the FDA Drug Shortage List[7]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[8]. What you actually pay moves with your dose and with whatever promotion happens to be running.
Tirzepatide Head-to-Head Comparisons
Short verdict pages setting Tirzepatide against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Pivotal Tirzepatide Trial Walkthroughs
The trials that produced the Tirzepatide label, taken endpoint by endpoint, with the figures read off the source.
Tirzepatide Patient Questions, Answered
Questions people actually asked about Tirzepatide in named subreddits, each answered from the published trial data.
Ranked PubMed Studies on Tirzepatide
The peer-reviewed studies on Tirzepatide and its neighbours that carry the most weight, gathered into lists. Every PMID was checked against PubMed esummary rather than recalled.
Related Research on Tirzepatide
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of August 2026
- 1.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 3.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 4.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 5.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
- 6.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 8.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary
The words sellers use, defined. Tap any term.
- Zepbound · Drugs and brands
- Mounjaro · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
- Dual agonist · Mechanism
- SURMOUNT-1 · Major trials
- SURMOUNT-OSA · Major trials
- Compounded GLP-1 · Pharmacy and drug forms
- Titration · Dosing